{
    "root": "34b810ad-5ee0-5373-e063-6394a90ac67f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Clonazepam",
    "value": "20250509",
    "ingredients": [
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "CLONAZEPAM",
            "code": "5PE9FDE8GB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3756"
        }
    ],
    "indications": {
        "text": "clonazepam useful alone adjunct treatment lennox-gastaut syndrome ( petit mal variant ) , akinetic , myoclonic seizures . patients absence seizures ( petit mal ) failed respond succinimides , clonazepam may useful . loss effect may occur course clonazepam treatment ( : loss effect ) .",
        "doid_entities": [
            {
                "text": "lennox-gastaut syndrome (DOID:0050561)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050561"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "lennox-gastaut syndrome",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_2382"
            }
        ]
    },
    "contraindications": {
        "text": "clonazepam available tablet . tablets administered water swallowing tablet whole .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "clonazepam tablets , usp available : 1 mg : light blue , flat-faced beveled edge tablets , unscored , debossed `` 2531 `` one side debossed `` v `` reverse side , available follows : ndc : 70518-1353-00 ndc : 70518-1353-01 ndc : 70518-1353-02 packaging : 30 1 blister pack packaging : 100 1 box packaging : 1 1 pouch dispense tight , light-resistant container defined usp/nf . store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "clonazepam contraindicated patients following conditions : history sensitivity benzodiazepines biochemical evidence significant liver disease acute narrow angle glaucoma ( may used patients open angle glaucoma receiving appropriate therapy ) .",
    "indications_original": "Clonazepam is useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic, and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam may be useful.\n                        Some loss of effect may occur during the course of clonazepam treatment (see\n \n  \n                              PRECAUTIONS: Loss of Effect\n                           ).",
    "contraindications_original": "Clonazepam is available as a tablet. The tablets should be administered with water by swallowing the tablet whole.",
    "warningsAndPrecautions_original": "Clonazepam Tablets, USP are available as:\n                  1 mg: light blue, flat-faced beveled edge tablets, unscored, debossed \"2531\" on one side and debossed \"V\" on the reverse side, available as follows:\n                  NDC: 70518-1353-00\n                  NDC: 70518-1353-01\n                  NDC: 70518-1353-02\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 100 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  \n                  Dispense in a tight, light-resistant container as defined in the USP/NF.\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature].\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Clonazepam is contraindicated in patients with the following conditions:\n                  \n                     History of sensitivity to benzodiazepines\n                     Clinical or biochemical evidence of significant liver disease\n                     Acute narrow angle glaucoma (it may be used in patients with open angle glaucoma who are receiving appropriate therapy).",
    "drug": [
        {
            "name": "Clonazepam",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3756"
        }
    ]
}